Twitter Facebook LinkedIn YouTube

Nuuvera Inc. started trading on the TSX Venture Exchange under the symbol NUU

Video Platform Video Management Video Solutions Video Player

Based in Ontario, Nuuvera is currently working in Germany, Malta and Italy and is exploring opportunities in several other countries, to develop commercial production and global distribution of medical grade cannabis in legalized markets.

Additional Information:

Company: Nuuvera Inc.
Website: http://www.nuuvera.com
Stock Symbol: TSXV: NUU
Date Published: Jan 9, 2018
Transcript: Available

Video Transcript:

I’m Megan Edwards for Investmentpitch Media

Nuuvera Inc. started trading on the TSX Venture Exchange under the symbol NUU, following approval of its qualifying transaction with Capital Pool Company “Mira IX Acquisition Corp”.

Based in Ontario, Nuuvera is currently working in Germany, Israel, Malta and Italy, and is exploring opportunities in several other countries, to develop commercial production and global distribution of medical grade cannabis in legalized markets.

Through its subsidiaries, Nuuvera holds a Dealer License under the Narcotic Control Regulations and Office of Controlled Substances.

The company is currently in the final stages of the Health Canada review process to become a Licensed Producer of medical marijuana under the ACMPR, and has recently received its “letter to build” approval.

Nuuvera recently purchased a 11,300 square-foot property in northern Germany, to build a premium vault storage system equipped with state-of-the-art security and related technology.

The facility is expected to meet the most stringent requirements for the storage of controlled substances in Germany and the EU.

Lorne Abony, CEO, stated: “This development is ground-breaking for Nuuvera. It is a critical element of our on-the-ground operations in Germany and throughout Europe. With a market of 82-million people, Germany represents a key growth opportunity in this emerging and rapidly growing global business.”

The Nuuvera facility will be built in two phases.

In phase one the storage system will be built and it is expected to be completed and fully operational in the second quarter of 2018.

In addition to storage capabilities, it is expected that in phase two the facility will also contain a GMP certified
packaging and processing facility, allowing Nuuvera to prepare bulk material shipped from Canada to Germany.

Hendrik Knopp, Managing Director of Nuuvera Germany, stated: “Nuuvera’s very quick assessment of the demand and needs in Germany are reflected in the significant and highly strategic investment the company is making here. We are very well-placed to immediately respond to market demand, while ensuring premium quality throughout the cultivation, processing, import, packaging, and shipment to pharmacies. Our corporate priority aligns perfectly with that of German physicians, pharmacists and lawmakers: that medical consumers receive top quality product on a consistent basis.”

The company is well financed, having recently completed a brokered private placement raising gross proceeds of $20 million through the issuance of 8 million subscription receipts priced at $2.50, from a syndicate led by GMP Securities, and including Clarus Securities, and Canaccord Genuity.

The shares are trading at $5.62 and with 79.9 million shares outstanding, the company is capitalized at $449 million.

For a more information, please visit the company’s website www.nuuvera.com or contact Lorne Abony, CEO, at 416-548-5998.

I’m Megan Edwards for Investmentpitch Media